Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

6.2K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.7K
5.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

4.4K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
4.4K
Molecular Factors Affecting Cell Division01:27

Molecular Factors Affecting Cell Division

4.1K
Several external and internal factors influence the initiation and inhibition of cell division. For instance, the death of nearby cells or the release of human growth hormone (hGH) promotes cell division. In contrast, lack of hGH or crowding of cells can inhibit cell division.
Several proteins function as internal regulators to ensure each cell cycle stage is completed faithfully before proceeding to the next. Regulator molecules may act directly or influence the activity or production of other...
4.1K
Negative Regulator Molecules01:23

Negative Regulator Molecules

39.2K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
39.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel Bioconjugate Materials: Synthesis, Characterization and Medical Applications.

Advanced healthcare materials·2025
Same author

Obesity and cancer: unravelling the microbiome's hidden role.

Frontiers in nutrition·2025
Same author

Obesity, Physical Activity, and Cancer Incidence in Two Geographically Distinct Populations; The Gulf Cooperation Council Countries and the United Kingdom-A Systematic Review and Meta-Analysis.

Cancers·2025
Same author

In Silico Analysis of Triamterene as a Potential Dual Inhibitor of VEGFR-2 and c-Met Receptors.

Journal of xenobiotics·2024
Same author

Identifying lifestyle factors associated to co-morbidity of obesity and psychiatric disorders, a pilot study.

Frontiers in public health·2023
Same author

Nanoparticle-mediated cancer cell therapy: basic science to clinical applications.

Cancer metastasis reviews·2023
Same journal

Epigenetic plasticity and chemoresistance in cancer: mechanisms, biomarkers, and translational opportunities for real-world evidence.

Frontiers in cell and developmental biology·2026
Same journal

Matched embryo-endometrium RNA-seq reveals coordinated but asymmetric transcriptomic reprogramming at the onset of early equine pregnancy.

Frontiers in cell and developmental biology·2026
Same journal

Myelin development in the peripheral nervous system of <i>Trachemys scripta</i>.

Frontiers in cell and developmental biology·2026
Same journal

A deep learning-based classification method for subclinical zonular laxity in AS-OCT images.

Frontiers in cell and developmental biology·2026
Same journal

Advancing fat graft survival: from adipose-derived stem cell mechanisms to next-generation regenerative strategies.

Frontiers in cell and developmental biology·2026
Same journal

CRISPR-based next-generation molecular diagnostics for bone infection.

Frontiers in cell and developmental biology·2026
See all related articles

Related Experiment Video

Updated: Apr 14, 2026

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation
09:09

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation

Published on: November 10, 2017

9.0K

Targeting cell cycle regulators in hematologic malignancies.

Eiman Aleem1, Robert J Arceci2

  • 1Department of Child Health, The Ronald A. Matricaria Institute of Molecular Medicine at Phoenix Children's Hospital, University of Arizona College of Medicine-Phoenix Phoenix, AZ, USA ; Department of Zoology, Faculty of Science, Alexandria University Alexandria, Egypt.

Frontiers in Cell and Developmental Biology
|April 28, 2015
PubMed
Summary
This summary is machine-generated.

Cyclin-dependent kinases (CDKs) are crucial regulators of cell cycle and stem cell renewal, making them targets for treating hematologic malignancies. Inhibitors of CDKs like CDK6, CDK1, and WEE-1 show promise in preclinical and clinical studies for leukemia treatment.

Keywords:
Cdk1Cdk19Cdk6Cdk8Cyclin CWee-1leukemiamouse models

More Related Videos

Measuring Cell Cycle Progression Kinetics with Metabolic Labeling and Flow Cytometry
11:23

Measuring Cell Cycle Progression Kinetics with Metabolic Labeling and Flow Cytometry

Published on: May 22, 2012

21.8K
Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols
12:02

Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols

Published on: June 6, 2017

28.8K

Related Experiment Videos

Last Updated: Apr 14, 2026

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation
09:09

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation

Published on: November 10, 2017

9.0K
Measuring Cell Cycle Progression Kinetics with Metabolic Labeling and Flow Cytometry
11:23

Measuring Cell Cycle Progression Kinetics with Metabolic Labeling and Flow Cytometry

Published on: May 22, 2012

21.8K
Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols
12:02

Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols

Published on: June 6, 2017

28.8K

Area of Science:

  • Oncology
  • Molecular Biology
  • Hematology

Background:

  • Hematologic malignancies disrupt normal blood cell production due to uncontrolled growth of abnormal stem cells.
  • Cyclin-dependent kinases (CDKs) regulate cell cycle, stem cell renewal, and other vital cellular processes.
  • Altered CDK activities are implicated in various human cancers, making them targets for drug development.

Purpose of the Study:

  • To review key cell cycle kinases involved in hematopoiesis and hematologic malignancies.
  • To summarize the role of specific kinases (CDK6, CDK1, WEE-1) in different leukemia types.
  • To present an overview of CDK-targeting compounds in clinical development and discuss combination therapies.

Main Methods:

  • Review of scientific literature focusing on cell cycle kinases in hematologic malignancies.
  • Summary of findings from mouse knockout experiments for CDK functions.
  • Compilation of data on clinical development of CDK inhibitors and combination therapies.

Main Results:

  • CDK6 is implicated in MLL-rearranged leukemia and acute lymphocytic leukemia.
  • CDK1 and its regulator WEE-1 are relevant in acute myeloid leukemia (AML).
  • Cyclin C/CDK8/CDK19 complexes are involved in T-cell acute lymphocytic leukemia.
  • Several CDK inhibitors (e.g., palbociclib, dinaciclib, MK-1775) are in clinical trials.
  • Combination therapy of cell cycle inhibitors with chemotherapy (e.g., cytarabine) shows potential.

Conclusions:

  • Selected cell cycle kinases are critical regulators in hematopoiesis and hematologic malignancies.
  • Targeting these kinases with inhibitors represents a promising therapeutic strategy.
  • Combination therapies may enhance treatment efficacy for hematologic malignancies like AML.